Patent SG-11201809237R-A (SG)
Title: Oxaborole esters and uses thereof
Inventor: AKAMA TSUTOMU
IPC: C07F5/02
Filed: 2017-05-01
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit VIII Hot 0 mu ioo Immo iflo oimIE (10) International Publication Number WO 2017/195069 Al (51) International Patent Classification: C07F 5/02 (2006.01) A61P 33/00 (2006.01) A61K 31/69 (2006.01) (21) International Application Number: PCT/IB2017/052522 (22) International Filing Date: 01 May 2017 (01.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/335,565 12 May 2016 (12.05.2016) US (71) Applicant: ANACOR PHARMACEUTICALS, INC. [US/US]; 1020 East Meadow Circle, Palo Alto, California 94303 (US). (72) Inventors: AKAMA, Tsutomu; 933 Berkshire Ave, Sun- nyvale, California 94087 (US). CARTER, David Scott; 1452 La Crosse Dr, Sunnyvale, California 94087 (US). HALLADAY, Jason S.; 16400 Hilow Rd., Los Gatos, California 95032 (US). JACOBS, Robert T.; 1849 Old College Circle, Wake Forest, North Carolina 27587 (US). LIU, Yang; 740 Polaris Ave, Foster City, California 94404 (US). PLATTNER, Jacob J.; 1026 Alvarado Road, Berke- ley, California 94705 (US). ZHANG, Yong-Kang; 5151 Westmont Ave, San Jose, California 95130 (US). WITTY, Michael John; c/o Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, California 94303 (US). (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(i)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) N O (57) : The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases 0 associated with parasites, such as Chagas Disease and African Animal Trypanosomosis. (54) Title: OXABOROLE ESTERS AND USES THEREOF